Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shukra Pharmaceuticals held an Extra-Ordinary General Meeting (EGM) on July 6, 2026, via video conferencing. One special resolution was put to vote: approval for the preferential issue of 46,43,000 convertible equity warrants to promoters for cash consideration, under SEBI (ICDR) Regulations, 2018. Out of 28,925 shareholders on record (cut-off date June 29, 2026), only 58 attended the meeting, and 13 cast valid votes through remote e-voting, totaling 9,772,995 shares. The resolution was passed unanimously with 100% votes in favor (9,772,995 shares) and 0% votes against. Promoter group voted 9,760,000 shares (all in favor), while public non-institutions voted 12,995 shares (all in favor). The scrutinizer, PCS Rupal Patel, certified the result.
Existing shareholders should note this is a promoter-related preferential allotment that could lead to equity dilution once warrants are converted. The 100% approval and lack of public opposition suggest institutional and retail shareholders did not raise objections, though the actual dilution impact depends on warrant exercise price and conversion terms not detailed in this filing.